

BAXTER INTERNATIONAL INC.
Franchise Sales by U.S. and International
Three-Month Periods Ending June 30, 2014 and 2013
(unaudited)
(\$ in millions)

	Q2 2014			Q2 2013			% Growth		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
BioScience									
Hemophilia	\$375	\$529	\$904	\$346	\$503	\$849	8%	5%	6%
BioTherapeutics	358	190	548	335	178	513	7%	7%	7%
BioSurgery	102	87	189	101	77	178	1%	13%	6%
Vaccines	-	110	110	-	98	98	-	12%	12%
Total BioScience	\$835	\$916	\$1,751	\$782	\$856	\$1,638	7%	7%	7%
Medical Products									
Fluid Systems	\$443	\$373	\$816	\$390	\$365	\$755	14%	2%	8%
Renal ¹	186	858	1,044	101	553	654	84%	55%	60%
Specialty Pharmaceuticals	174	230	404	163	203	366	7%	13%	10%
BioPharma Solutions	94	155	249	110	146	256	(15%)	6%	(3%)
Total Medical Products ¹	\$897	\$1,616	\$2,513	\$764	\$1,267	\$2,031	17%	28%	24%
Total Baxter ¹	\$1,732	\$2,532	\$4,264	\$1,546	\$2,123	\$3,669	12%	19%	16%

¹ Includes Gambro net sales of \$408 million in the second quarter of 2014. Renal sales excluding Gambro decreased by 3% at actual rates and 1% at constant rates during the second quarter of 2014. Medical Products net sales excluding Gambro grew 4% at both actual rates and constant rates during the second quarter of 2014. Total Baxter net sales excluding Gambro grew 5% at both actual rates and constant rates during the second quarter of 2014.